A multicenter trial demonstrated that radiation-emitting metallic stents (REMS) combined with hepatic arterial infusion chemotherapy (HAIC) significantly outperformed self-expandable metallic stents (SEMS) in patients with unresectable Bismuth type III or IV perihilar cholangiocarcinoma. The median overall survival was 10.2 months for REMS compared to 6.7 months for SEMS (p=0.002). Additionally, median time to symptomatic progression and stent patency were also longer with REMS, with improvements noted in physical functioning and fatigue.
Randomized Controlled Trial by Chen Q, Ge NJ (…) Lu J et 19 al. in Int J Surg
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.